Suven Life Sciences secures three Product Patents

30 Dec 2014 Evaluate

Suven Life Sciences has received the grant of one product patent from Eurasia, one product patent from Japan and one product patent from Mexico corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of thirteen granted patents from Eurasia, twelve granted patents from Japan and seventeen product patents from Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

Suven Life Sciences Share Price

128.65 -2.80 (-2.13%)
08-Nov-2024 00:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1811.35
Dr. Reddys Lab 1281.85
Cipla 1591.75
Lupin 2104.30
Zydus Lifesciences 968.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.